Eyenovia

107 articles with Eyenovia

• Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas

  1/31/2023

  Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8.

• Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

  1/12/2023

  Eyenovia, Inc. today announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops.

• Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology

  12/22/2022

  While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used has gone largely unchanged in the last century.

• Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

  12/20/2022

  Eyenovia, Inc. (NASDAQ: EYEN) today announced that the company will participate at the 2023 International Consumer Electronics Show, which is being held January 5-8 at the Las Vegas Convention Center.

• Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

  12/13/2022

  Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for MydCombi™ ophthalmic spray.

• Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

  12/8/2022

  Eyenovia, Inc. today announced that Bren Kern, who currently serves as Eyenovia’s Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1st.

• Eyenovia to Present at Upcoming BTIG Ophthalmology Day

  11/23/2022

  Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022.

• Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Eyenovia, Inc. announced its financial and operating results for the third quarter ended September 30, 2022.

• Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10, 2022

  11/3/2022

  Eyenovia, Inc. announced that the Company will release financial results for the third quarter ended September 30, 2022 on Thursday, November 10, 2022, after the markets close.

• Eyenovia to Present at the American Academy of Optometry’s Annual Meeting

  10/21/2022

  Eyenovia, Inc. announced the company will present at the 2022 American Academy of Optometry’s Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center.

• Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

  10/20/2022

  Eyenovia, Inc. (NASDAQ: EYEN) today announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia.

• Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.

  9/30/2022

  Eyenovia, Inc. today announced the planned retirement of lead independent director, Ken Lee, Jr., effective today, September 30, 2022.

• Eyenovia to Present at Upcoming September 2022 Healthcare Conferences

  9/7/2022

  Eyenovia, Inc. announced they will present at the R.W. Baird Global Healthcare Conference taking place on September 13-14, 2022 at the Intercontinental New York Barclay Hotel and the Ladenburg Thalmann Healthcare Conference taking place on September 29, 2022 at the Sofitel Hotel in New York City.

• Eyenovia to Participate in Multiple Medical Meetings in September 2022

  9/6/2022

  Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print therapeutics, announced that the company will be participating in multiple medical meetings in September.

• Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

  8/30/2022

  Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser.

• Eyenovia Reports Second Quarter 2022 Financial Results

  8/10/2022

  Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced its financial and operating results for the second quarter ended June 30, 2022.

• Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10

  8/4/2022

  Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.

• Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

  7/27/2022

  Eyenovia, Inc. today announced the appointment of current Chief Operating Officer Michael Rowe as the Company’s new Chief Executive Officer, effective August 1, 2022.

• Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

  7/18/2022

  Eyenovia, Inc. today provided an update on its expanded manufacturing capabilities and also announced the appointment of Bren Kern as Senior Vice President of Manufacturing and Operations.

• 

  Clinical Catch-Up: Vertex, Ayala, Arrowhead, Dyne & More

  7/11/2022

  Ayala announced positive data for its desmoid tumor treatment, while Vertex and Dyne announced the FDA had lifted the hold on their clinical studies.